IGL believes that pharmaceutical companies investing in research and development of new medicines are entitled to protection against unfair competition. The right to patent inventions is essential for the industry to obtain new and better medicines for treatment of diseases. At the same time, IGL believes it is essential that these rights do not reach an extent that allows them to prevent competition on medicine.

All Danish patients should have access to safe, effective and affordable medicines as soon as the patents on the original medicines expire. This benefits patients as well as Danish society, which is currently burdened by the rising cost of medicine.